Thyrocare Technologies, which operates a chain of diagnostic and preventive care laboratories, today said it has reappointed A Velumani as its MD and CEO for a period of three years.
The company would also acquire the trademark 'Whaters' from Velumani, its registered owner, for a token consideration of Re 1. Velumani has agreed for the token amount as a gesture of goodwill instead of Rs 1 crore approved by the board of directors in 2016, it added.
Similarly, Nueclear Healthcare Ltd, its wholly-owned subsidiary, would be acquiring the trademark 'Nueclear' from Velumani for a token consideration of Re 1 instead of Rs 1 crore approved by NHL board last year, it added.
"Velumani, whose remuneration is presently Rs 10 lakh per month, has decided to draw a token salary of Re 1 per month from April 1, 2017, as a gesture of goodwill," Thyrocare said in a regulatory filing.
It also announced the reappointment of A Sundararaju as ED and CFO for three years.
The company has also decided to give loans to Nueclear Healthcare "at arm's length basis to help them acquire costly equipments like Cyclotron, PET CT Scan machines etc for setting up additional scanning centres".
Disclaimer: No Business Standard Journalist was involved in creation of this content
